substituted by 1-15 R^{39}, halogen, –CN,–C(=O)OR^{30}, –$NR^{32}R^{33}$, –OR^{30}, =O, –S(=O)$_n R^{30}$, where n is 0, 1, or 2.

65. A compound as defined in any of claims 1, 56-58 or 63-64 wherein G is a group of formula 

; and R^7 is C_{3-11}cycloalkyl optionally substituted by 1-21 R^{19} and R^8 and R^9 are H.

66. A pharmaceutical composition comprising a compound of Formula (I) according to any of claims 1-65 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient.

67. The use of a compound of Formula (I) according to any of claims 1-65 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of an aPKC-dependent disorder or condition.

substituted by 1-15 R^{39}, halogen, –CN,–C(=O)OR^{30}, –$NR^{32}R^{33}$, –OR^{30}, =O, –$S(=O)_nR^{30}$, where n is 0, 1, or 2.

65. A compound as defined in any of claims 1 56-58 or 63-64 wherein G is a group of formula 

; and R^7 is C_{3-11}cycloalkyl optionally substituted by 1-21 R^{19} and R^8 and R^9 are H.

66. A pharmaceutical composition comprising a compound of Formula (I) according to any of claims 1-65 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient.

67. Use of a compound of Formula (I) according to any of claim 1-65 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of a proliferative disorder.

68. The use according to claim 67 wherein the proliferative disorder is cancer.

69. The use according to claim 68 wherein the cancer is selected from squamous cell carcinoma, leukaemia, prostate cancer, non-Hodgkin's lymphoma, endometrial cancer, lung cancer and breast cancer.